The current price of CGEN is $1.92 — it has decreased by 5.42% since the previous close. Data as of Nov 5, 2026.
CGEN is down 4.95% over the past week, down 16.88% over the past month and up 17.07% over the past year. The price is below its 200-day moving average of $2.29.
Of the 5 analysts covering Compugen Ltd., 5 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Compugen Ltd. has a market capitalization of $181.87M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Compugen Ltd. posted a loss of $0.07 per share against an estimate of -$0.08002, beating expectations by 12.52%. Upcoming reports are listed in the earnings calendar.
Compugen Ltd. reported revenue of $2.6M in its most recent quarter, which has increased by 107.00% compared with the same quarter a year earlier. Analysts had expected $1.28M.
Companies most comparable to Compugen Ltd. include Nuvectis Pharma, Inc., Cybin Inc., Innate Pharma S.A., Molecular Partners AG and Milestone Pharmaceuticals Inc.
In the latest trading session CGEN moved between $1.87 and $2.00, a range of 7.03% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Compugen Ltd. shows a sell rating today. Technical ratings are indicators, not investment advice.
Over the past 52 weeks CGEN has traded between $1.43 and $3.24. The current price is 40.74% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.